Skip to main content

Table 2 CIMP definitions and prevalence in studies on survival after specific colorectal cancer therapies according to CIMP status

From: Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review

Definition First author (year) Common CIMP genes Other CIMP genes CIMP category CIMP+/-H prevalence
            CIMP+ CIMP−  
   CACNA1G IGF2 NEUROG1 RUNX3 SOCS1 CRABP1 MLH1 p16 MINT1 MINT2 MINT31   CIMP-H CIMP-L CIMP-N  
D 2 Min (2011) [25] + + + + +         ≥3/5 1–2/5 0/5 13.9 %
  Donada (2013) [40] + + + + +         ≥3/5 1–2/5 0/5 18.3 %
  Jo (2012) [44] + + + + +         ≥3/5 0–2/5 10.0 %
  Shiovitz (2014) [35] + + + + +         ≥3/5 0–2/5 23.6 %
D 3 Han (2013) [45] + + + + + + + +      ≥5/8 1–4/8 0/8 7.8 %
D 5 Rijinsoever (2003) [41]         +   +   MDR1 ≥2/3 0–1/3 32.5 %
D 8 Jover (2011) [5] +   + + +   +       ≥3/5 0–2/5 29.5 %
D 10 Wang (2014) [36]        + + +    MGMT, P14ARF ≥3/5 <3/5 24.0 %
D 14 Li (2014) [34]     +    + + +   + MGMT, APC ≥4/7 1–3/7 0/7 13.1 %
D 15 Ogino (2007) [42] + + + + + + + + +   + MGMT, IGFBP3, WRN ≥9/13a 1–8/13 0/13 10.0 %
               ≥7/13b 1–6/13 0/13 16.7 %
D 16 Shen (2007) [43]         + +   + P14ARF ≥2/4 0–1/4 15.4 %
  1. aCIMP classification 1 of the study. CIMP-H was defined as ≥9/13 methylated markers, CIMP-L as 1/13 to 8/13 methylated markers and CIMP-N as 0/13 methylated markers
  2. bCIMP classification 2 of the study. CIMP-H was defined as ≥7/13 methylated markers, CIMP-L as 1/13 to 6/13 methylated markers and CIMP-N as 0/13 methylated markers